Merck Sharp & Dohme LLC v. Johns Hopkins University

Bruce M. Wexler

Preston K. Ratliff, II

Mark J. Stewart

Naveen Modi

Daniel Zeilberger

David J. Feigenbaum

Anita Meiklejohn

Todd G. Miller

Kristi Sawert

Grace J. Kim

Nicholas Stephens

Matthew Chun

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Merck challenges MSI-H cancer therapy patent: anticipation & obviousness argued against all 28 claims for pembrolizumab based on a clinical trial protocol.

Merck Sharp & Dohme LLC

Johns Hopkins University

Last Docket Entry Date

Total Docket Entries

IPR2024-00622 | Merck Sharp & Dohme LLC v. Johns Hopkins University | Ex Parte

Patent Trial and Appeal Board

Judge	Cases	Inst. Rate	FWD Inv. Rate
Deborah Katz	60+	80%	88%
Devon Z Newman	70+	63%	75%
Sheridan K Snedden	500+	65%	75%
Sheridan K Snedden	500+	65%	75%

Name	Ratings
Paul Hastings LLP	L5 A
Naveen Modi	L5 A
Preston K. Ratliff, II	L3 A
Bruce M. Wexler	L1 C
Mark J. Stewart	L1 C
Daniel Zeilberger	L1 C
David J. Feigenbaum	-- -- --

Name	Ratings
Fish & Richardson	L5 A
Nicholas Stephens	L3 D
Kristi Sawert	L1 C
Anita Meiklejohn	-- -- --
Todd G. Miller	-- -- --
Grace J. Kim	-- -- --
Matthew Chun	-- -- --